Rituxan (Rituximab) for RA, NHL, CLL, GPA and MPA
INDICATIONS RITUXAN ® (Rituximab) is indicated for the treatment of: Low-grade or follicular CD20-positive non-Hodgkin's lymphoma as a single-agent therapy in patients whose disease recurred or did not respond to initial treatment Follicular CD20-positive...